# EDGAR Filing Document

**Accession Number:** 0002022416
**File Stem:** 0001178913-26-002981
**Filing Date:** 2026-5
**Character Count:** 36559
**Document Hash:** eb889405dc7c880e5fbb17a89ee06a0b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-002981.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001178913-26-002981

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260528

**DATE AS OF CHANGE**: 20260528

**EFFECTIVENESS DATE**: 20260528

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silexion Therapeutics Corp
- **CENTRAL INDEX KEY:** 0002022416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-296303
- **FILM NUMBER:** 261035597

**BUSINESS ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606
- **BUSINESS PHONE:** 972-8-6286005

**MAIL ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biomotion Sciences
- **DATE OF NAME CHANGE:** 20240506

As filed with the Securities and Exchange Commission on May 28, 2026

#### Registration No. 333-

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM S-8

#### REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

---

| |
|:---|
| **Silexion Therapeutics Corp** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Cayman Islands** | **Not applicable** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **12 Abba Hillel Road**<br> **Ramat Gan, Israel** | **5250606** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

---

| |
|:---|
| **Silexion Therapeutics Corp 2024 Equity Incentive Plan** |
| (Full title of the plan) |

---

---

| |
|:---|
| **Puglisi & Associates<br> 850 Library Avenue, Suite 204<br> Newark, DE 19711<br> Telephone: (302) 738-6680** |
| (Name, address, telephone number,<br> including area code, of agent for service) |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

![](image1.jpg)

#### EXPLANATORY NOTE
This registration statement on Form S-8 (this "**Registration Statement**") registers the offer, issuance and sale of a total of up to 438,567 ordinary shares, par value $0.0135 per share ("**ordinary shares**"), of Silexion Therapeutics Corp, a Cayman Islands exempted company ("**Silexion**," the "**Company**," the "**Registrant**," "**our company**," "**we**" or "**us**"), that are issuable to Silexion's and/or its subsidiaries' officers, employees, directors and consultants under the Silexion Therapeutics Corp 2024 Equity Incentive Plan (the "**2024 Plan**"). The ordinary shares registered hereunder represent additional shares allocated to, and issuable from time to time under, the 2024 Plan, which allocation occurred automatically effective as of January 1, 2026 pursuant to an amendment to the "evergreen" provision of the 2024 Plan approved by the shareholders of the Company at an extraordinary general meeting of the Company originally held on April 28, 2026 and reconvened on May 5, 2026. The amendment to the "evergreen" provision, retroactive to January 1, 2026, resulted in an immediate increase of 438,567 ordinary shares to the pool of shares reserved for issuance under the 2024 Plan as of that date (in addition to the 156,333 ordinary shares already added to that pool as of January 1, 2026 under the prior "evergreen" provision, the offer, issuance and sale of which shares were registered under the Company's registration statement on Form S-8, Securities and Exchange Commission (the "**Commission**" or the "**SEC**") File Number [333-293582](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000574/zk2634406.htm) filed with the SEC on February 19, 2026). After that amendment to the "evergreen" provision of the 2024 Plan, the total number of reserved shares under the 2024 Plan and all other equity incentive plans of the Company is equal to 10% of Silexion's issued and outstanding share capital on a fully diluted basis as of January 1, 2026.

Pursuant to Instruction E of Form S-8, the contents of the Company's registration statements on Form S-8, Commission File Numbers [333-285891](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000893/zk2532874.htm), [333-289746](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003009/zk2533683.htm), and [333-293582](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000574/zk2634406.htm), filed with the SECon March 18, 2025, August 20, 2025, and February 19, 2026 respectively, covering offers, issuances and sales of ordinary shares under the 2024 Plan, are incorporated herein by reference, and made a part of this Registration Statement, except as amended or supplemented by the information set forth below.

#### PART I

#### INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

#### Item 1. Plan Information.\*

#### Item 2. Registrant Information and Employee Plan Annual Information.\*
\*The documents containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933 (the "**Securities Act**") and the introductory note to Part I of Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference into this registration statement pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

------

#### PART II

#### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

#### Item 3. Incorporation of Documents by Reference.
The following documents filed by Silexion with the Commission are incorporated herein by reference:

(a) Silexion's Annual Report on [Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0002022416/000117891326000953/zk2634529.htm) for the fiscal year ended December 31, 2025, filed with the
 Commission on March 17, 2026, as amended by Amendment No. 1 thereto, filed with the Commission on May 19, 2026 (the "**2025 Form 10-K** ").

(b) Silexion's Quarterly Report on Form 10-Q for the quarter ended [March 31, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0002022416/000117891326002744/zk2635243.htm) filed with the Commission
 on May 15, 2026.

(c) Silexion's Current Reports on Form 8-K filed with the Commission on the following dates:

(i) [March 23, 2026;](https://www.sec.gov/ix?doc=/Archives/edgar/data/0002022416/000117891326001597/zk2634902.htm)

(ii) [March 25, 2026;](https://www.sec.gov/ix?doc=/Archives/edgar/data/0002022416/000117891326001722/zk2634957.htm)

(iii) [May 5, 2026;](https://www.sec.gov/ix?doc=/Archives/edgar/data/0002022416/000117891326002393/zk2635202.htm) 

(iv) [May 15, 2026.](https://www.sec.gov/ix?doc=/Archives/edgar/data/0002022416/000117891326002739/zk2635351.htm) and

(v) [May 26, 2026.](https://www.sec.gov/ix?doc=/Archives/edgar/data/2022416/000117891326002900/zk2635400.htm)

(d) The description of Silexion's ordinary shares contained in Silexion's registration statement on Form 8-A, filed by Silexion with the Commission on August 15, 2024, as updated by [Exhibit 4.1](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_4-1.htm) to the 2025 Form 10-K, and any amendment or report filed for the purpose of further updating that description.

In addition, all documents subsequently filed by Silexion with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, (the "**Exchange Act**"), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of filing of such documents. Silexion is not incorporating by reference any document or portion thereof, whether specifically listed above or to be filed in the future, that is not deemed to be "filed" with the Commission.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document which also is or deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

#### Item 8. Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| [4.1.1](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex3-1_silexion.htm) | [Amended and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences) (incorporated by reference to Exhibit 3.1 to Silexion's Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex3-1_silexion.htm) |
| [4.1.2](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_3-1.htm) | [Ordinary Resolution Effecting 1-for-9 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit 3.1 to Silexion's Current Report on Form 8-K filed with the SEC on November 29, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_3-1.htm) |
| [4.1.3](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/exhibit_3-1.htm) | [Ordinary Resolution Effecting 1-for-15 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit 3.1 to Silexion's Current Report on Form 8-K filed with the SEC on July 29, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/exhibit_3-1.htm) |
| [4.1.4](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002985/exhibit_3-1.htm) | [Ordinary Resolution Effecting Increase to Authorized Share Capital of Silexion to $121,500 (9,000,000 ordinary shares, par value $0.0135) (incorporated by reference to Exhibit 3.1 to Silexion's Current Report on Form 8-K filed with the SEC on August 19, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002985/exhibit_3-1.htm) |
| [4.1.5](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/exhibit_3-1.htm) | [Ordinary Resolution Effecting Increase to Authorized Share Capital of Silexion to $796,500 (59,000,000 ordinary shares, par value $0.0135) (incorporated by reference to Exhibit 3.1 to Silexion's Current Report on Form 8-K filed with the SEC on May 5, 2026)](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/exhibit_3-1.htm) |
| [4.2.1](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-12_silexion.htm) | [Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to Silexion's Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-12_silexion.htm) |
| [4.2.2](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002192/zk2533359.htm) | [Amendment to Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Annex B to Silexion's Definitive Proxy Statement on Schedule 14A for its 2025 annual general meeting, filed with the SEC on June 16, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002192/zk2533359.htm) |
| [4.2.3](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002037/zk2635046.htm) | [Amendment to Section 5(b)(i) of the Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Annex C to Silexion Therapeutics Corp's Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 9, 2026)](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002037/zk2635046.htm) |
| [<u>5.1</u>](exhibit_5-1.htm) | [<u>Opinion of Conyers Dill & Pearman LLP</u>](exhibit_5-1.htm) |
| [<u>23.1</u>](exhibit_23-1.htm) | [<u>Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm</u>](exhibit_23-1.htm) |
| [<u>23.2</u>](exhibit_5-1.htm) | [<u>Consent of Conyers Dill & Pearman LLP (contained in Exhibit 5.1)</u>](exhibit_5-1.htm) |
| [24.1](#POWEROFATTORNEY) | [Power of Attorney (included on signature page)](#POWEROFATTORNEY) |
| [<u>107</u>](exfilingfees.htm) | [<u>Filing fee table</u>](exfilingfees.htm) |

---

------

#### Item 9. Undertakings
(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate,
 represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not
 exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the
 changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in this Registration Statement; and

(iii) To include any material information with respect to the Plans not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

*provided*, *however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and
 the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Ramat Gan , Israel, on May 28, 2026.

---

| | |
|:---|:---|
| **SILEXION THERAPEUTICS CORP** | **SILEXION THERAPEUTICS CORP** |
| By: | <u>/s/ Ilan Hadar</u> |
|  | Name: Ilan Hadar |
|  | Title: Chairman and Chief Executive Officer |

---

#### POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, each person whose signature appears below hereby constitutes and appoints Ilan Hadar and Mirit Horenshtein Hadar, and each of them, as his or her true and lawful attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities to sign any and all amendments, including post-effective amendments, to this Registration Statement on Form S-8 (including, without limitation, any additional registration statement filed pursuant to Rule 462 under the Securities Act of 1933, as amended), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and with full power of substitution; hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Ilan Hadar | Chairman and Chief Executive Officer | May 28, 2026 |
| Ilan Hadar | *(Principal Executive Officer)* |  |
| /s/ Mirit Horenshtein Hadar | Chief Financial Officer and Secretary | May 28, 2026 |
| Mirit Horenshtein Hadar | *(Principal Financial and Accounting Officer)* |  |
| /s/ Dror J. Abramov | Director | May 28, 2026 |
| Dror J. Abramov |  |  |
| /s/ Ruth Alon | Director | May 28, 2026 |
| Ruth Alon |  |  |
| /s/ Avner Lushi | Director | May 28, 2026 |
| Avner Lushi |  |  |
| /s/ Shlomo Noy | Director | May 28, 2026 |
| Shlomo Noy |  |  |
| /s/ Amnon Peled | Director | May 28, 2026 |
| Amnon Peled |  |  |

---

------

**AUTHORIZED REPRESENTATIVE**

Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Silexion Therapeutics Corp, has signed this registration statement in Newark, Delaware, on May 28, 2026.

---

| | |
|:---|:---|
| **PUGLISI & ASSOCIATES** | **PUGLISI & ASSOCIATES** |
| By: | <u>/s/ Donald J. Puglisi</u> |
| Name: | Donald J. Puglisi |
| Title: | Authorized Representative |

---

------

## Exhibit 5.1

------

<u>**Exhibit 5.1**</u>

---

| | |
|:---|:---|
| ![](image00007.jpg) | **CONYERS DILL & PEARMAN LLP**<br> SIX, 2nd Floor, Cricket Square<br> PO Box 2681, Grand Cayman KY1-1111<br> Cayman Islands<br> T +1 345 945 3901<br> **conyers.com**<br>|

---

28 May 2026

Silexion Therapeutics Corp

c/o Conyers Trust Company (Cayman) Limited

Cricket Square, Hutchins Drive

P.O. Box 2681

Grand Cayman, KY1-1111

Cayman Islands

Ladies and Gentlemen,

**Re: Silexion Therapeutics Corp** (the "**Company**")

We have acted as special legal counsel in the Cayman Islands to the Company in connection with the Company's Registration Statement on Form S-8 filed with the United States Securities and Exchange Commission (the "**Commission**") on or around the date of this opinion (the "**Registration Statement**") relating to the Company's registration and proposed offering (the "**Offering**") of up to a maximum aggregate amount of 438,567 ordinary shares with par value $0.0135 per share (collectively, the "**Ordinary Shares**"), issuable pursuant to potential future grants under the Company's 2024 Equity Incentive Plan, as amended (the "**2024 Plan**"), all as more particularly described in the Registration Statement.

**1.**&nbsp;&nbsp;&nbsp;&nbsp; **DOCUMENTS REVIEWED**

For the purposes of giving this opinion, we have examined copies of:

<br> (i) the Registration Statement;

<br> (ii) the certificate of incorporation of the Company dated 2 April 2024;

(iii) the amended and restated memorandum and articles of association of the Company adopted on 15 August 2024 (the "**Articles**"), including any amendments to the authorised share capital as of the date of this opinion;

(iv) the unanimous written resolutions of the board of directors of the Company dated 13 August 2024 and the minutes of a meeting of the board of directors of the Company held on 31 March 2026 (the "**Resolutions**");

(v) a Certificate of Good Standing (the "**Certificate of Good Standing**") dated 11 May 2026 issued by the Registrar of Companies in relation to the Company; and

<br> (vi) such other documents and made such enquiries as to questions of law as we have deemed necessary in order to render the opinion set forth below.

------

**2.**&nbsp;&nbsp;&nbsp;&nbsp; **ASSUMPTIONS**

We have assumed:

<br> (a) the genuineness and authenticity of all signatures and the conformity to the originals of all copies (whether or not certified) examined by us and the authenticity and completeness of the originals from which such copies were taken;

<br> (b) the accuracy and completeness of all factual representations made in the Registration Statement and other documents reviewed by us;

(c) that where a document has been examined by us in draft form, it will be or has been executed in substantially the form of that draft, and where a number of drafts of a document have been examined by us all changes thereto have been marked or otherwise drawn to our attention;

<br> (d) that the resolutions contained in the Resolutions were passed by unanimous written resolutions or at a duly convened meeting of the board of directors of the Company, remain in full force and effect and have not been and will not be rescinded or amended;

<br> (e) that there is no provision of the law of any jurisdiction, other than the Cayman Islands, which would have any implication in relation to the opinions expressed herein;

<br> (f) that at the time of issuance, any Ordinary Shares shall be issued by the Company against payment in full, which shall be equal to at least the par value thereof, and shall be duly registered in the Company's register of members;

<br> (g) that at the time of issuance, the Company will have sufficient authorised share capital to effect the issue of any Ordinary Shares at the time of issuance;

(h) there are no records of the Company (other than the Resolutions), agreements, documents or arrangements other than the documents expressly referred to herein as having been examined by us which materially affect, amend or vary the transactions envisaged in the documents expressly referred to herein or restrict the powers and authority of the directors of the Company in any way or which would affect any opinion given herein;

(i) the capacity, power and authority of all parties other than the Company to enter into and perform their obligations under any and all documents entered into by such parties in connection with the issuance of the Ordinary Shares, and the due execution and delivery thereof by each party thereto;

<br> (j) the effectiveness under the laws of the United States of America of the Registration Statement and that the Registration Statement will be duly filed with and declared effective by the Commission;

<br> (k) that the Registration Statement declared effective by the Commission will be in substantially the same form as that examined by us for purposes of this opinion;

Page 2 of 4

------

<br> (l) that there is no provision of the law of any jurisdiction, other than the Cayman Islands, which would have any implication in relation to the opinions expressed herein;

(m) the legality, validity and binding effect under the laws of the State of Israel (the "**Foreign Laws**") of the 2024 Plan, which are expressed to be governed by the Foreign Laws, in accordance with their respective terms;

(n) the validity and binding effect under the 2024 Plan of the submission by the Company to the exclusive jurisdiction of the courts sitting in the State of Israel (the "**Foreign Courts**");

<br> (o) that each of the documents reviewed by us are, or will be, legal, valid, binding and enforceable against all relevant parties in accordance with their terms under all relevant laws (other than, with respect to the Company, the laws of the Cayman Islands); and

<br> (p) that there is no contractual or other prohibition or restriction (other than as arising under Cayman Islands law) binding on the Company prohibiting or restricting it from entering into and performing its obligations under the documents reviewed by us.

**3.**&nbsp;&nbsp;&nbsp;&nbsp; **QUALIFICATIONS**

(a) The term "enforceable" as used in this opinion means that an obligation is of a type which the courts of the Cayman Islands enforce. It does not mean that those obligations will be enforced in all circumstances. In particular, the obligations of the Company in connection with any Registered Security and any indenture or other agreement or document relating thereto:

(i) will be subject to the laws from time to time in effect relating to bankruptcy, insolvency, liquidation, possessory liens, rights of set off, reorganisation, amalgamation, merger, consolidation, moratorium, bribery, corruption, money laundering, terrorist financing, proliferation financing or any other laws or legal procedures, whether of a similar nature or otherwise, generally affecting the rights of creditors as well as applicable international sanctions;

<br> (ii) will be subject to statutory limitation of the time within which proceedings may be brought;

<br> (iii) will be subject to general principles of equity and, as such, specific performance and injunctive relief, being equitable remedies, may not be available;

(iv) may not be given effect to by a Cayman Islands court if and to the extent they constitute the payment of an amount which is in the nature of a penalty; and

(v) may not be given effect by a Cayman Islands court to the extent that they are to be performed in a jurisdiction outside the Cayman Islands and such performance would be illegal under the laws of that jurisdiction. Notwithstanding any contractual submission to the exclusive or non-exclusive jurisdiction of specific courts, a Cayman Islands court has inherent discretion to stay or allow proceedings in the Cayman Islands against the Company if there are other proceedings simultaneously underway against the Company in another jurisdiction.

Page 3 of 4

------

<br> (b) We have made no investigation of and express no opinion in relation to the laws of any jurisdiction other than the Cayman Islands.

<br> (c) This opinion is to be governed by and construed in accordance with the laws of the Cayman Islands and is limited to and is given on the basis of the current law and practice in the Cayman Islands.

<br> (d) This opinion is issued solely for the purposes of the filing of the Registration Statement and the offering of the Ordinary Shares by the Company and is not to be relied upon in respect of any other matter.

**4.**&nbsp;&nbsp;&nbsp;&nbsp; **OPINIONS**

On the basis of and subject to the foregoing, we are of the opinion that:

(a) The Company is duly incorporated and existing under the laws of the Cayman Islands and, based on the Certificate of Good Standing, is in good standing. Pursuant to the Companies Act of the Cayman Islands (the "**Act**"), a company is deemed to be in good standing if all fees and penalties under the Act have been paid and the Registrar of Companies has no knowledge that the Company is in default under the Act.

(b) The issue of the Ordinary Shares has been duly authorised and, when issued and paid for in accordance with the Resolutions, the Articles, the 2024 Plan and the Registration Statement, as applicable, and entered on the register of members of the Company, the Ordinary Shares will be validly issued, fully paid and non-assessable (which term when used herein means that no further sums are required to be paid by the holders thereof in connection with the issue of such Ordinary Shares).

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to our firm under the caption "Description of Ordinary Shares" and "Legal Matters" in the prospectus forming a part of the Registration Statement. In giving this consent, we do not hereby admit that we are experts within the meaning of Section 11 of the Securities Act or that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission promulgated thereunder.

Yours faithfully,

/s/ Conyers Dill & Pearman LLP

#### Conyers Dill & Pearman LLP

#### <br>

#### Page 4 of 4

## Exhibit 23.1

#### Exhibit 23.1

#### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Silexion Therapeutics Corp of our report dated March 17, 2026 relating to the financial statements of Silexion Therapeutics Corp, which appears in Silexion Therapeutics Corp's Annual Report on Form 10-K for the year ended December 31, 2025.

---

| | |
|:---|:---|
| Tel-Aviv, Israel | /s/ Kesselman & Kesselman |
| May 28, 2026 | Certified Public Accountants (Isr.) |
|  | A member firm of PricewaterhouseCoopers International Limited |

---

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Silexion Therapeutics Corp**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Ordinary shares, par value $0.0135 per share ("ordinary shares") | Other | 438567 | $0.4205 | $184417.42 | 0.0001381 | $25.47 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $184417.42  |  | $25.47  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $25.47  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> 1. In accordance with Rule 416(a) under the Securities Act of 1933, as amended ("Securities Act"), this registration statement shall also cover any additional ordinary shares as may be offered or issued to prevent dilution resulting from stock splits, stock dividends, or similar transactions pursuant to the terms of the Silexion Therapeutics Corp 2024 Equity Incentive Plan (the "2024 Plan"). 2. Estimated in accordance with Rules 457(c) and 457(h) solely for the purpose of calculating the registration fee on the basis of $0.4205 per share, which represents the average of the high ($0.435) and low ($0.406) prices of the ordinary shares as reported on the Nasdaq Capital Market on May 27, 2026. 3. Represents ordinary shares available for issuance pursuant to potential future grants under the 2024 Plan.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---